AR243934A1 - Un metodo para obtener n-alcanoil(c4-c8)gbmp a partir de gbmp n-desacetilado y metodo para preparar conjugados de proteinas inmunologicas con dicho producto n-desacetilado. - Google Patents

Un metodo para obtener n-alcanoil(c4-c8)gbmp a partir de gbmp n-desacetilado y metodo para preparar conjugados de proteinas inmunologicas con dicho producto n-desacetilado.

Info

Publication number
AR243934A1
AR243934A1 AR90318627A AR31862790A AR243934A1 AR 243934 A1 AR243934 A1 AR 243934A1 AR 90318627 A AR90318627 A AR 90318627A AR 31862790 A AR31862790 A AR 31862790A AR 243934 A1 AR243934 A1 AR 243934A1
Authority
AR
Argentina
Prior art keywords
conjugate vaccine
polysaccharide conjugate
meningococcal polysaccharide
improved
improved meningococcal
Prior art date
Application number
AR90318627A
Other languages
English (en)
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Application granted granted Critical
Publication of AR243934A1 publication Critical patent/AR243934A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AR90318627A 1989-12-14 1990-12-14 Un metodo para obtener n-alcanoil(c4-c8)gbmp a partir de gbmp n-desacetilado y metodo para preparar conjugados de proteinas inmunologicas con dicho producto n-desacetilado. AR243934A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44819589A 1989-12-14 1989-12-14

Publications (1)

Publication Number Publication Date
AR243934A1 true AR243934A1 (es) 1993-09-30

Family

ID=23779371

Family Applications (1)

Application Number Title Priority Date Filing Date
AR90318627A AR243934A1 (es) 1989-12-14 1990-12-14 Un metodo para obtener n-alcanoil(c4-c8)gbmp a partir de gbmp n-desacetilado y metodo para preparar conjugados de proteinas inmunologicas con dicho producto n-desacetilado.

Country Status (30)

Country Link
US (3) US5576002A (es)
EP (1) EP0504202B1 (es)
JP (1) JP2637845B2 (es)
KR (1) KR0158436B1 (es)
CN (4) CN1049223C (es)
AR (1) AR243934A1 (es)
AT (1) ATE121947T1 (es)
AU (1) AU641715B2 (es)
BR (1) BR9007917A (es)
CA (1) CA2071811C (es)
CZ (1) CZ283530B6 (es)
DE (1) DE69019164T2 (es)
DK (1) DK0504202T3 (es)
ES (1) ES2071288T3 (es)
FI (2) FI104539B (es)
HR (1) HRP920872A2 (es)
HU (2) HU218146B (es)
IE (1) IE68414B1 (es)
IL (1) IL96676A (es)
IN (1) IN171747B (es)
NO (2) NO305275B1 (es)
NZ (1) NZ236471A (es)
PH (1) PH30305A (es)
PL (2) PL166659B1 (es)
RO (1) RO111416B1 (es)
RU (1) RU2105568C1 (es)
SI (1) SI20008B (es)
WO (1) WO1991008772A1 (es)
YU (1) YU24391A (es)
ZA (1) ZA9010065B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
DK0504202T3 (da) * 1989-12-14 1995-10-02 Ca Nat Research Council Forbedret meningokok-polysaccharid-konjugat vaccine
EP0667787B1 (en) * 1992-09-24 2001-07-18 Brigham And Women's Hospital Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
ATE400295T1 (de) * 1995-06-07 2008-07-15 Glaxosmithkline Biolog Sa Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freiem trägerprotein
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
ZA97248B (en) * 1996-01-18 1997-07-18 Rohm & Haas Method for identifying and quantifying polymers utilizing immunoassay techniques
ATE252602T1 (de) * 1996-08-27 2003-11-15 Chiron Corp Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen
PT939647E (pt) † 1996-08-27 2002-04-29 Chiron Corp Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US6413520B1 (en) 1997-06-24 2002-07-02 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
US6030619A (en) * 1997-08-27 2000-02-29 Chiron Corporation Molecular mimetics of meningococcal B epitopes
CZ302615B6 (cs) 1997-12-23 2011-08-03 Baxter Healthcare S.A. Zpusob cištení kapsulárních polysacharidu od bunecných komponent gramnegativních a grampozitivních bakterií a modifikovaný kapsulární polysacharid
HUP0103100A3 (en) * 1998-08-19 2005-11-28 Baxter Healthcare Sa Immunogenic betha-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6518037B2 (en) * 1999-11-12 2003-02-11 University Of Iowa Research Foundation Two-component system that controls bacterial membrane synthesis
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
WO2002083711A2 (en) 2001-04-17 2002-10-24 Chiron Corporation Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
PT1490409E (pt) * 2002-03-26 2009-04-03 Novartis Vaccines & Diagnostic Sacáridos modificados possuindo uma estabilidade melhorada em água
US20040219160A1 (en) * 2003-03-31 2004-11-04 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
KR101113726B1 (ko) * 2003-08-12 2012-02-27 리폭센 테크놀로지즈 리미티드 단백질 유도 및 컨쥬게이션용 시알산 유도체
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
KR20070060069A (ko) 2004-06-23 2007-06-12 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 다당류 유도체 및 면역반응의 유도에서의 용도
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
PE20110072A1 (es) 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP1872791A1 (en) 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
US20100189740A1 (en) * 2007-06-20 2010-07-29 Francis Michon Modified polysaccharides for conjugate vaccines
US8815253B2 (en) 2007-12-07 2014-08-26 Novartis Ag Compositions for inducing immune responses
EP2387417B1 (en) 2009-01-16 2016-05-11 University of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal salmonella
JP6273200B2 (ja) 2011-07-12 2018-01-31 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 脂質含有ｐｓａ組成物、その単離の方法および使用の方法
EP2752403A1 (de) * 2013-01-08 2014-07-09 Sika Technology AG Amin für emissionsarme Epoxidharz-Produkte
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
SG11201906519RA (en) * 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
DK0504202T3 (da) * 1989-12-14 1995-10-02 Ca Nat Research Council Forbedret meningokok-polysaccharid-konjugat vaccine

Also Published As

Publication number Publication date
KR0158436B1 (ko) 1998-12-01
CA2071811A1 (en) 1991-06-15
CN1036504C (zh) 1997-11-26
HUT64480A (en) 1994-01-28
EP0504202A1 (en) 1992-09-23
ATE121947T1 (de) 1995-05-15
RO111416B1 (ro) 1996-10-31
WO1991008772A1 (en) 1991-06-27
NO307835B1 (no) 2000-06-05
BR9007917A (pt) 1992-10-20
NO922316D0 (no) 1992-06-12
HU9201966D0 (en) 1992-10-28
SI20008A (sl) 2000-02-29
NO973311L (no) 1992-08-14
IE68414B1 (en) 1996-06-12
AU641715B2 (en) 1993-09-30
DE69019164T2 (de) 1995-09-07
YU24391A (sh) 1995-12-04
NO973311D0 (no) 1997-07-17
SI20008B (en) 2001-02-28
FI922737A0 (fi) 1992-06-12
CN1036522C (zh) 1997-11-26
ZA9010065B (en) 1992-02-26
NO305275B1 (no) 1999-05-03
CN1100428A (zh) 1995-03-22
FI104539B (fi) 2000-02-29
NO922316L (no) 1992-08-14
IE904513A1 (en) 1991-06-19
PH30305A (en) 1997-02-20
CN1049223C (zh) 2000-02-09
NZ236471A (en) 1992-10-28
IL96676A0 (en) 1991-09-16
PL288271A1 (en) 1991-12-16
RU2105568C1 (ru) 1998-02-27
PL166035B1 (pl) 1995-03-31
ES2071288T3 (es) 1995-06-16
PL166659B1 (pl) 1995-06-30
US5902586A (en) 1999-05-11
IL96676A (en) 1996-09-12
HU218146B (hu) 2000-06-28
CA2071811C (en) 2003-11-04
DK0504202T3 (da) 1995-10-02
CN1072506C (zh) 2001-10-10
CN1096516A (zh) 1994-12-21
HRP920872A2 (en) 1997-06-30
AU6898791A (en) 1991-07-18
JP2637845B2 (ja) 1997-08-06
DE69019164D1 (de) 1995-06-08
FI19991917A (fi) 1999-09-09
US5576002A (en) 1996-11-19
IN171747B (es) 1992-12-26
US5683699A (en) 1997-11-04
CN1100656A (zh) 1995-03-29
CN1055541A (zh) 1991-10-23
JPH05505392A (ja) 1993-08-12
CZ283530B6 (cs) 1998-04-15
EP0504202B1 (en) 1995-05-03
CZ628490A3 (en) 1997-12-17

Similar Documents

Publication Publication Date Title
AR243934A1 (es) Un metodo para obtener n-alcanoil(c4-c8)gbmp a partir de gbmp n-desacetilado y metodo para preparar conjugados de proteinas inmunologicas con dicho producto n-desacetilado.
GB8907914D0 (en) Vaccine preparation
HU896283D0 (en) Colon-selective, peroral medical preparation
GB8924438D0 (en) Vaccine composition
EP0262876A3 (en) Nucleoside-phospholipid conjugate
HUP9802664A3 (en) Modified meningococcal polysaccharide conjugate vaccines and modified polysaccharides
EP0454735A4 (en) Vaccine composition
EP0468714A3 (en) Peptide-polysaccharide-protein conjugate vaccines
PT86286A (en) Conjugate vaccine
AU1118888A (en) Conjugate malaria vaccine
GB9017370D0 (en) Tuberculosis vaccine
GB8918689D0 (en) 25/15 vaccine
EP0504136A4 (en) Tolerogenic immunoglobulin-protein conjugates
AP9000165A0 (en) Vaccine composition
GB2232681B (en) Nitro-p-phenylenediamine derivatives
ZA907863B (en) Vaccine conjugate
GB8912496D0 (en) Vaccines
ZA92536B (en) Pneumococcal polysaccharide conjugate vaccine
AU5560886A (en) Klebsiella capsular polysaccharide vaccine
EP0453452A4 (en) Vaccine
ZA88792B (en) Conjugate malaria vaccine
GB8922651D0 (en) Vaccine
ZA909516B (en) Novel vaccine
ZA90766B (en) Vaccine composition
GB8628286D0 (en) Polymer-peptide conjugate